Canopy Growth's Stock Just Dropped -- Here's Why I'm Still Not Buying

Canopy Growth remains under pressure, with the stock down more than 12% in May and the company still struggling to generate profit. The recent C$125 million acquisition of profitable MTL Cannabis is too small to offset Canopy's latest quarterly net loss of nearly C$45.8 million on revenue of C$54.5 million, and the article expects further dilutive share issues. It also highlights ongoing regulatory and competitive headwinds in Canada and limited benefit from recent U.S. cannabis reform.

Analysis

CGC is still in the classic late-stage “survival equity” phase: operating leverage is absent, capital needs are persistent, and every incremental improvement gets diluted away before it can compound. The real issue is not that the recent acquisition is small; it is that any modestly profitable asset gets absorbed into a balance sheet that is structurally loss-making, so the market should treat the deal as a financing event with an EBITDA veneer rather than a genuine turnaround catalyst.

The second-order winner is not necessarily a named competitor so much as the higher-quality operators with cleaner capital structures and better access to U.S. optionality. If federal U.S. reform keeps progressing unevenly, capital will continue to migrate toward names that can self-fund growth and monetize medical/recreational adjacency without repeated equity issuance. That dynamic is especially bearish for TLRY and other sector peers because weak sentiment in one balance sheet-poor cannabis name tends to compress multiples across the whole sub-sector.

The catalyst path remains skewed negative over the next 3-6 months: if operating losses do not narrow meaningfully, CGC will likely need either another equity raise or a more aggressive asset sale, both of which would pressure the stock. The only plausible reversal is a material regulatory step-change in the U.S. that meaningfully expands addressable demand or improves taxation economics, but that is a 12-24 month call and still not enough if the company cannot fund the bridge. In other words, the equity is trading on optionality that management has repeatedly failed to monetize into per-share value.

Contrarianly, the stock can still rally hard in short bursts if retail positioning gets crowded short and cannabis legislation headlines hit. But that would be a tradeable squeeze, not a fundamental re-rating; the right frame is that the market is underestimating dilution risk and overestimating the value of small profitable assets inside an unprofitable roll-up.

Key Decisions for Investors

• Short CGC on rallies over the next 1-3 months; use strength tied to regulatory headlines or sector sympathy as entry, with a thesis that dilution/financing risk outweighs any acquisition-related optimism.
• Pair trade: long higher-quality U.S.-exposed cannabis operator vs short CGC for 3-6 months; the spread should benefit if the market starts discriminating between self-funding businesses and serial diluters.
• Avoid TLRY on a standalone basis; if forced into the sector, prefer a market-neutral position because weak CGC sentiment can bleed into the entire group and compress valuation multiples.
• If trading options, consider buying CGC puts with 2-4 month tenor into any post-news pop; defined-risk downside exposure is favorable because the path to value destruction is slower but more probable than a genuine turnaround.
• Cover some or all CGC shorts only if there is a credible capital-market backstop or a concrete U.S. legalization catalyst with a timeline under 6 months; absent that, upside is likely headline-driven while downside is balance-sheet driven.